EUR / USD 1.1652 (-0.59%)|USD / JPY 109.4455 (0.24%)
ИндексМесяцГод
Индекс МосБиржи+2.4%+18.5%
USD/RUB-1.7%+10.0%
EUR/RUB-4.8%+14.5%
Золото-1.8%+14.1%
Мы в соцсетях:

AMAG Pharmaceutical, акция обыкновенная (US00163U1060, AMAG)

Общая информация

ЭмитентAMAG Pharmaceutical
Типакция обыкновенная
ISIN-кодUS00163U1060
Количество34 326 636

NASDAQ

ТикерAMAG

Профиль эмитента

Полное названиеAMAG Pharmaceuticals, Inc.
ОтрасльМедицина и здравоохранение
Сайт Посмотреть сайт эмитента
 
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. Feraheme is approved for use in the treatment of both dialysis and non-dialysis dependent chronic kidney disease (CKD) patients. The Company’s principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). In December 2011, Feraheme was also granted marketing approval in Canada for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. GastroMARK, which is marketed and sold under the trade name Lumirem outside of the United States, is the Company’s oral contrast agent used for delineating the bowel in magnetic resonance imaging (MRI), and is approved and marketed in the United States, Europe, and other countries through its licensees.

Динамика стоимости акции AMAG Pharmaceutical, акция обыкновенная

NASDAQ, $NASDAQ, $

График архивных значений стоимости акции ()



Регистрация
Напомнить пароль

0.00%